Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.

Maximilian TrumJohannes RiechelElisa SchollmeierSimon Lebek Philipp HegnerKathrin ReuthnerSilvia HeersKaroline KellerMichael WesterSusanne KlattNazha Hamdani Zdenek ProvaznikChristof SchmidLars Siegfried MaierMichael ArztStefan Wagner

Published in: Cardiovascular research (2024)

We show for the first time increased Na influx in human atrial cardiomyocytes from HFpEF patients, partly due to increased late INa and enhanced NHE1-mediated Na influx. Empagliflozin inhibits Na influx and late INa, which could contribute to anti-arrhythmic effects in patients with HFpEF.

Keyphrases

end stage renal disease
atrial fibrillation
endothelial cells
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
high glucose
catheter ablation
patient reported